Cantargia’s Nadunolimab Shows Promise in Overcoming Cancer Immunosuppression

Cantargia AB ( (SE:CANTA) ) has shared an announcement.

Cantargia AB has published preclinical data in Cancer Discovery, demonstrating that targeting IL1RAP can counteract tumor-driven systemic immunosuppression, which is a significant barrier to effective cancer immunotherapy. The findings, supported by clinical data, show that nadunolimab can reduce immunosuppressive cells and enhance the efficacy of cancer vaccines, suggesting a promising potential for improving cancer treatment outcomes.

More about Cantargia AB

Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. It has established a platform centered around the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. The company’s oncology program features the antibody nadunolimab (CAN04), studied primarily in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Cantargia also has a second development program, CAN10, targeting autoimmune and inflammatory diseases.

YTD Price Performance: -2.61%

Average Trading Volume: 2,500

Technical Sentiment Signal: Buy

Current Market Cap: €36.77M

See more data about CANTA stock on TipRanks’ Stock Analysis page.